Drugs for Cellular Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 179)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Thiotepa |
Approved, Investigational |
Phase 2, Phase 3 |
|
52-24-4 |
5453 |
Synonyms:
Girostan
Rethio
Tepadina
Tespa
Tespamin
Thio tepa
|
Thiophosphamide
Thioplex
Thiotepa
Thio-tepa
Triethylenethiophosphoramide
Tris(1-aziridinyl)phosphine sulfide
|
|
2 |
|
Etoposide |
Approved |
Phase 2, Phase 3 |
|
33419-42-0 |
36462 |
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
Eto gry
Eto-gry
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
etoposide
|
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
3 |
|
Valproic acid |
Approved, Investigational |
Phase 2, Phase 3 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 PP (base)
2 Propylpentanoic acid
2-N-Propyl-N-valerate
2-n-propyl-n-valeric acid
2-n-Propyl-n-valeric acid
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-propyl-pentanoic acid
2-Propylpentanoic acid
2-Propylpentanoic Acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-propylvaleric acid
2-Propylvaleric acid
2-Propylvaleric Acid
4-Heptanecarboxylate
4-heptanecarboxylic acid
4-Heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
Abbott 44090
AC1L1F7T
AC1Q2ULA
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acide valproique [INN-French]
Acido valproico
ácido valproico
Acido valproico [INN-Spanish]
acidum valproicum
Acidum valproicum
Acidum valproicum [INN-Latin]
AI3-10500
Alti-valproic
Alti-Valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
BIDD:GT0858
BRN 1750447
C07185
Calcium valproate
Calcium, valproate
CHEBI:39867
CHEMBL109
CID3121
Convulex
Convulsofin
CPD000499581
D00399
DB00313
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetate
di-n-propylacetic acid
Di-n-propylacetic acid
Di-N-propylacetic acid
Di-n-propylessigsaeure
Di-N-propylessigsaeure
Di-n-propylessigsaure
Di-N-propylessigsaure
Di-n-propylessigsäure
Di-n-propylessigsaure [German]
Dipropyl acetate
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DivK1c_000273
DOM-divalproex
Dom-valproate
Dom-Valproic
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
EINECS 202-777-3
Epiject i.v.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
|
KBio2_004845
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
Magnesium valproate
Med valproic
Med Valproic
MLS001076682
MLS001335927
MLS001335928
MLS002415770
MolPort-001-791-895
Mylproin
Myproate
Myproic acid
Myproic Acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
nchembio.79-comp4
nchembio815-comp21
n-Dipropylacetic acid
N-Dipropylacetic acid
n-DPA
N-DPA
NINDS_000273
Novo-divalproex
Novo-valproic
Novo-Valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC 93819
NSC93819
Nu-valproic
Nu-Valproic
P0823
P6273_SIGMA
PEAC
Penta-valproic
Penta-Valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic Acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
Sandoz valproic
Savicol
SBB065764
Semisodium valproate
Semisodium Valproate
SMR000499581
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
SPBio_000912
Spectrum_000521
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Sprinkle
Stavzor
UNII-614OI1Z5WI
Valcote
Valparin
valproate
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
valproic acid
Valproic acid
VALPROIC ACID
Valproic acid (USP)
Valproic acid [USAN:INN:BAN]
Valproic acid usp
Valproic acid USP
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproic Acid, Sodium Salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
WLN: QVY3 & 3
|
|
4 |
|
Vincristine |
Approved, Investigational |
Phase 3 |
|
2068-78-2, 57-22-7 |
5978 |
Synonyms:
(+)-Vincristine
22-Oxovincaleukoblastin
22-oxo-Vincaleukoblastine
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
Cellcristin
CHEBI:28445
CID5978
Citomid
D08679
DB00541
EINECS 200-318-1
Farmistin
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
Leucristine
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
LS-228
Marqibo
NCGC00163700-01
NCI60_026703
NCI-C04864
NSC-67574
Onco TCS
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
|
Onkocristin
PFS, Vincasar
Sulfate, vincristine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
vincristine
Vincristine
Vincristine (INN)
Vincristine [INN:BAN]
Vincristine sulfate
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristinum
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
Z-D-Val-Lys(Z)-OH
|
|
5 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
84093 441203 2767 |
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatin
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
|
CPDC
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
6 |
|
Trofosfamide |
Investigational |
Phase 2, Phase 3 |
|
22089-22-1 |
|
7 |
|
Etoposide phosphate |
|
Phase 2, Phase 3 |
|
|
|
8 |
|
Psychotropic Drugs |
|
Phase 2, Phase 3 |
|
|
|
9 |
|
Anticonvulsants |
|
Phase 2, Phase 3 |
|
|
|
10 |
|
Mesna |
Approved, Investigational |
Phase 2 |
|
3375-50-6 |
598 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-mercaptoethanesulfonic acid
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-mercaptoethanesulphonic acid
2-Mercaptoethanesulphonic acid
2-mercaptoethylsulfonate
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-sulfanylethylsulfonate
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzima M
Coenzym m
Coenzym M
Coenzyme m
CoM
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
reduced coenzyme M
Reduced coenzyme m
reduced CoM
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Î’-mercaptoethanesulfonate
β-mercaptoethanesulfonic acid
Î’-mercaptoethanesulfonic acid
Î’-mercaptoethanesulphonate
Î’-mercaptoethanesulphonic acid
|
|
11 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
341031-54-7, 557795-19-4 |
5329102 |
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
|
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU010398
SU-010398
Su-011248
SU011248
SU011248 L-malate salt
SU-011248 L-malate salt
SU11248
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
Sunitanib
sunitinib
Sunitinib
Sunitinib (free base)
Sunitinib (INN)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
sunitinibum
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
|
|
12 |
|
Oxaliplatin |
Approved, Investigational |
Phase 2 |
|
61825-94-3 |
5310940 9887054 6857599 43805 |
Synonyms:
ACT 078
ACT-078
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Eloxatine
Elplat
Foloxatine
L-OHP
L-OHP CPD
|
Oxalatoplatin
Oxalatoplatinum
oxaliplatin
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
13 |
|
Pemetrexed |
Approved, Investigational |
Phase 2 |
|
150399-23-8, 137281-23-3 |
446556 60843 |
Synonyms:
(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate
(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
137281-23-3
150399-23-8
1juj
2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
AC1L1U1D
AC1L2PDW
AC1L98DY
AC1L9JT6
AC1OCF51
AC1Q5R1W
Alimta
ALIMTA
Alimta (TN)
Bio-0078
C20H19N5O6.2Na
C20H21N5O6
CHEBI:195145
CHEBI:43746
CHEBI:474008
CHEMBL1200373
CHEMBL225072
CHEMBL59843
CID125891
CID394493
CID446556
CID60843
CID6918197
D03828
D07472
DB00642
disodium (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
disodium (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
|
Disodium, pemetrexed
HSDB 7316
I06-1253
I06-1294
I06-2128
L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt
LS-172988
LS-173384
LY 231,514
LY 231514
LY-231,514
LY-2315
LY231514
LY-231514
LY231514 disodium
LYA
MTA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid
NCGC00167517-01
nchembio.108-comp6
NCI60_035021
NSC698037
Pemetrexed
Pemetrexed (INN)
Pemetrexed [INN:BAN]
Pemetrexed disodium
Pemetrexed Disodium
Pemetrexed disodium (USAN)
Pemetrexed disodium [USAN]
Rolazar
ST51053024
Tifolar
UNII-04Q9AIZ7NO
UNII-2PKU919BA9
|
|
14 |
|
Lomustine |
Approved, Investigational |
Phase 2 |
|
13010-47-4 |
3950 |
Synonyms:
(Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]
1-(2-chloroethyl)-3-cyclohexylnitrosourea
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
13010-47-4
AC-10564
AC1L1H2T
AI3-52779
Belustine
Bristol myers squibb brand OF lomustine
Bristol Myers Squibb Brand of Lomustine
Bristol-myers squibb brand OF lomustine
Bristol-Myers Squibb Brand of Lomustine
BRN 2125058
C9H16ClN3O2
CCNU
CCNU [Chloroethyl nitrosoureas]
CCRIS 860
Cecenu
CeeNU
CeeNU (TN)
CeeNU, CCNU, Lomustine
CHEMBL514
Chloroethylcyclohexylnitrosourea
CID3950
CINU
Cyclohexyl chloroethyl nitrosourea
D00363
D008130
DB01206
EINECS 235-859-2
FT-0083566
HMS2090A17
HSDB 6519
I06-0087
|
ICIG 1109
Lomustina
Lomustina [INN-Spanish]
lomustine
Lomustine
Lomustine (USAN/INN)
Lomustine [USAN:BAN:INN]
Lomustine medac brand
Lomustine medac Brand
Lomustinum
Lomustinum [INN-Latin]
LS-728
medac Brand of Lomustine
Medac brand OF lomustine
MolPort-001-768-818
N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea
NCGC00167466-01
NCI60_041743
NCI-C04740
NCIMech_000220
NPFAPI-06
NSC 79037
NSC79037
NSC-79037
OR5087
RB 1509
Rhone Poulenc Rorer Brand of Lomustine
Rhône poulenc rorer brand OF lomustine
Rhone-Poulenc Rorer Brand of Lomustine
Rhône-poulenc rorer brand OF lomustine
S1840_Selleck
SRI 2200
UNII-7BRF0Z81KG
WLN: L6TJ AMVNNO&2G
ZINC03831006
|
|
15 |
|
Ivosidenib |
Approved, Investigational |
Phase 2 |
|
1448347-49-6 |
71657455 |
Synonyms:
|
16 |
|
Fenofibric acid |
Approved |
Phase 2 |
|
42017-89-0 |
|
17 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662 |
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
18 |
|
Cytarabine |
Approved, Investigational |
Phase 2 |
|
147-94-4 |
6253 |
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
147-94-4
1-Arabinofuranosylcytosine
1-b-D-Arabinofuranosylcytosine
1beta -Arabinofuranasylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta -D-Arabinofuranosylcytosine
1-beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosyl-cytosine
1-beta-D-Arabinofuranosylcytosine, cytosine arabinoside
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1beta-D-Arabinosylcytosine
1-beta-D-Arabinosylcytosine
1-beta-D-Arabinosyl-cytosine
1-Î’-D-arabinofuranosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2(1H)-pyrimidinone
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
4-Amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
4-Amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
Alexan
AR3
Ara C
Arabinocytidine
Arabinocytosine
Arabinofuranosylcytosine
Arabinoside C
Arabinoside, cytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
AraC
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Aracytidine
Ara-Cytidine
Aracytin
Aracytine
Arafcyt
beta Ara C
beta -Arabinosylcytosine
beta -Cytosine arabinoside
beta -D-Arabinosylcytosine
beta-Ara c
beta-Ara C
beta-Arabinosylcytosine
beta-Cytosine arabinoside
Beta-cytosine arabinoside
beta-D-Arabinosylcytosine
BIDD:GT0371
BIDD:PXR0139
BTB15125
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
Citarabina
|
Citarabina [INN-Spanish]
CPD000449317
Cytarabin
Cytarabina
cytarabine
Cytarabine
Cytarabine (JP15/USP/INN)
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine hydrochloride
cytarabine liposome injection
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar u
Cytosar-u
CytosarU
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-b-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-1-β-D-arabinofuranoside
Cytosinearabinoside
Cytosine-b-D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta -D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosine-beta-D-arabinofuranoside
cytosine-β-D-arabinofuranoside
Cytosine-β-D-arabinofuranoside
D00168
DB00987
Depocyt
Depocyt (liposomal)
Depocyt (TN)
Depocyte
DepoCyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Hydrochloride, cytarabine
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
Lopac0_000316
LS-860
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
Spongocytidine
SR-01000075773-3
Tarabine
TL8001048
U 19920A
U-19,920
U-19920
Udicil
UNII-04079A1RDZ
ZINC03795098
|
|
19 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-rapamycin
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AC-722
Ambotz53123-88-9
Antibiotic ay 22989
Antibiotic AY 22989
AY 22989
AY22989
AY-22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
FT-0082351
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
|
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MolMap_000043
MolPort-003-959-433
MS-R001
NCGC00021305-05
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
Rapammune
Rapamune
Rapamune (TN)
rapamycin
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin from Streptomyces hygroscopicus
Rapamycin Immunosuppressant Drug
Rapamysin
RPM
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
sirolimus
Sirolimus
Sirolimús
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
Sirolimusum
SMP1_000255
SMR000058564
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
Wy 090217
WY-090217
|
|
20 |
|
Mebendazole |
Approved, Vet_approved |
Phase 2 |
|
31431-39-7 |
4030 |
Synonyms:
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamate methyl ester
(5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
(5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
(5-Benzoyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester
2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester
2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI)
31431-39-7
46404_FLUKA
46404_RIEDEL
5-Benzoyl-2-benzimidazolecarbamic acid methyl ester
5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester
AB00052203
Abello farmacia brand OF mebendazole
Abello Farmacia Brand of Mebendazole
AC-12064
AC1L1H98
AC1Q44DR
AKOS000539066
Anti worm
Anti Worm
Anti-worm
Anti-Worm
Ardeypharm brand OF mebendazole
Ardeypharm Brand of Mebendazole
Bantenol
Banworm
BAS 00341140
Besantin
BIDD:GT0087
Bio-0458
Bio-0803
Boots brand OF mebendazole
Boots Brand of Mebendazole
Boots threadworm treatment
Boots Threadworm Treatment
BPBio1_000257
BRD-K77987382-001-01-7
BRD-K77987382-001-06-6
BSPBio_000233
BSPBio_003178
Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester
Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI)
Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester
CAS-31431-39-7
CBDivE_010559
CCRIS 4479
CHEBI:6704
CHEMBL685
CID4030
CPD000036734
D00368
D008463
DB00643
Degort's brand OF mebendazole
Degort's Brand of Mebendazole
Diba brand OF mebendazole
Diba Brand of Mebendazole
DivK1c_000751
EINECS 250-635-4
Elfar brand OF mebendazole
Elfar Brand of Mebendazole
Equivurm Plus
Esteve brand OF mebendazole
Esteve Brand of Mebendazole
Healthypharm brand OF mebendazole
Healthypharm Brand of Mebendazole
HMS1536H11
HMS1568L15
HMS1921F03
HMS2090B03
HMS2092B15
HMS502F13
HSDB 3232
I06-2075
IDI1_000751
Janssen brand OF mebendazole
Janssen Brand of Mebendazole
KBio1_000751
KBio2_001778
KBio2_004346
KBio2_006914
KBio3_002398
KBioGR_000712
KBioSS_001778
Leidapharm brand OF mebendazole
Leidapharm Brand of Mebendazole
Lomper
LS-48951
M2523_FLUKA
M2523_SIGMA
Madicure
MBDZ
Mebendan
Mebendazol
Mebendazol [INN-Spanish]
mebendazole
|
Mebendazole
Mébendazole
Mebendazole (JAN/USP)
Mebendazole (JAN/USP/INN)
Mebendazole [USAN:INN:BAN:JAN]
Mebendazole(USAN)
MEBENDAZOLE, 99%
Mebendazolum
Mebendazolum [INN-Latin]
Mebenoazole
Mebenvet
Mebex
Mebutar
methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate
methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate
Methyl 5-benzoyl benzimidazole-2-carbamate
Methyl 5-benzoyl-2-benzimidazolecarbamate
Methyl 5-benzoyl-2-benzimidazolylcarbamate
Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate
Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate
methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate
methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate
MLS000028491
MolPort-000-765-625
MolPort-001-889-615
N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle
N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]
N-2 (5-Benzoyl-benzimidazole) carbamate de methyle
N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]
NCGC00016806-01
NCGC00016806-02
NCGC00021698-03
NCGC00021698-04
NCGC00021698-05
NCGC00021698-06
NINDS_000751
Norgine brand OF mebendazole
Norgine Brand of Mebendazole
Noverme
NSC 184849
NSC184849
Oprea1_278237
Oprea1_768530
Ovitelmin
Pantelmin
Pfizer brand OF mebendazole
Pfizer Brand of Mebendazole
Prestwick_310
Prestwick0_000217
Prestwick1_000217
Prestwick2_000217
Prestwick3_000217
Pripsen mebendazole
Pripsen Mebendazole
Probes1_000013
Probes2_000149
R 17,635
R 17635
R17635
R-17635
SAM002548959
SMR000036734
SPBio_001442
SPBio_002154
Spectrum_001298
SPECTRUM1501110
Spectrum2_001401
Spectrum3_001439
Spectrum4_000416
Spectrum5_001381
Sqworm
SSL Brand of Mebendazole
SSL Brand OF mebendazole
STK093862
Streger brand OF mebendazole
Streger Brand of Mebendazole
Sufil
Surfont
Taxandria brand OF mebendazole
Taxandria Brand of Mebendazole
Tedec meiji brand OF mebendazole
Tedec Meiji Brand of Mebendazole
Telmin
TimTec1_000869
TL8002405
UNII-81G6I5V05I
Vermicidin
Vermicol
Vermidil
Vermin
Vermirax
Vermox
Vermox (TN)
Verpanyl
Versid
Wormkuur
ZINC00121541
|
|
21 |
|
Piperazine |
Approved, Vet_approved |
Phase 2 |
|
110-85-0 |
4837 |
Synonyms:
1,4 Diazacyclohexane
1,4 Piperazine
1,4-Diazacyclohexane
1,4-Diethylenediamine
1,4-Piperazine
110-85-0
14007-05-7 (unspecified hydrobromide)
142-63-2 (hexahydrate)
142-64-3 (di-hydrochloride)
14538-56-8 (phosphate[1:1])
16832-43-2 (unspecified hydrate)
1951-97-9 (unspecified phosphate)
3597-26-0 (unspecified sulfate)
5-23-01-00030 (Beilstein Handbook Reference)
6094-40-2 (unspecified hydrochloride)
7542-23-6 (mono-hydrochloride)
8017-90-1
8027-81-4
8057-14-5 (unspecified salt)
80621_FLUKA
854880-15-2
861800-35-3
AB1003720
AC1L1J2E
AC1Q1IA7
AC1Q1IA8
AC1Q1IA9
AKOS000269028
Anthalazine
Antiren
AR-1L1009
ARONIS23910
Asca-Trol No. 3
BIDD:GT0273
BRN 0102555
C07973
CCRIS 5950
CHEBI:28568
CHEMBL1412
CID4837
D00807
DB00592
Diethylenediamine
Diethyleneimine
Dispermine
DivK1c_000038
EINECS 203-808-3
Eraverm
Eraverm (VAN)
Fluphenazine dihydrochloride
Hexahydro-1,4-diazine
Hexahydropyrazine
HMS1920H20
HMS2092A03
HMS500B20
HSDB 1093
I14-11172
IDI1_000038
InChI=1/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H
Jsp000824
KBio1_000038
KBio2_001593
KBio2_004161
KBio2_006729
KBioSS_001593
LS-517
LTBB000432
Lumbrical
MolPort-000-872-010
NCGC00094762-01
NCGC00094762-02
nchembio814-comp12
NCIOpen2_000984
NCIOpen2_000988
NCIOpen2_001024
NCIOpen2_001031
NCIOpen2_001033
NCIOpen2_001071
NCIOpen2_001073
NCIOpen2_001111
NCIOpen2_001151
NCIOpen2_001231
NCIOpen2_001262
NCIOpen2_001269
NCIOpen2_004830
|
NCIOpen2_004834
NCIOpen2_004862
NCIOpen2_004874
NCIOpen2_004904
NCIOpen2_004910
NCIOpen2_004914
NCIOpen2_004942
NCIOpen2_004952
NCIOpen2_004954
NCIOpen2_004982
NCIOpen2_004992
NCIOpen2_004994
NCIOpen2_005022
NCIOpen2_005032
NCIOpen2_005034
NCIOpen2_005062
NCIOpen2_005072
NCIOpen2_005102
NCIOpen2_005108
NCIOpen2_005145
NCIOpen2_005182
NCIOpen2_005185
NCIOpen2_005187
NCIOpen2_005200
NCIOpen2_005575
NCIOpen2_005980
NCIOpen2_009422
NINDS_000038
NSC 474
NSC474
P0446
P0447
P45907_SIAL
Piperazidine
Piperazin
Piperazin [German]
Piperazin [Germany]
Piperazina
piperazine
PIPERAZINE (HEXAHYDRATE)
Piperazine (USP)
Piperazine [UN2579] [Corrosive]
Piperazine [UN2579] [Corrosive]
Piperazine [USAN]
Piperazine anhydrous
Piperazine diacetate
Piperazine dihydrochloride
Piperazine Dihydrochloride Dihydrochloride Hydrate
Piperazine hexahydrate
Piperazine Hexa-Hydrate
Piperazine hydrate
Piperazine hydrobromide
Piperazine hydrochloride
Piperazine monohydrochloride
Piperazine phosphate
Piperazine phosphate (1:1)
Piperazine phosphate anhydrous
Piperazine salt
Piperazine sulfate
Piperazine tartrate
Piperazine tartrate (1:1), (R-(r*,r*))-isomer
Piperazine tartrate, (R-(r*,r*))-isomer
Piperazine, anhydrous
piperazinium oleate
Piperazinium oleate
Pipersol
Pripsen
Pyrazine hexahydride
Pyrazine, hexahy
PZE
Spectrum_001113
SPECTRUM1500490
Spectrum5_001817
UN2579
UNII-1RTM4PAL0V
Upixon
Uvilon
Vermex
Vermizine
Vermizine (TN)
WLN: T6M DMTJ
Worm-A-Ton
Worm-away
Wurmirazin
|
|
22 |
|
Palbociclib |
Approved, Investigational |
Phase 2 |
|
571190-30-2 |
11431660 5005498 5330286 |
Synonyms:
2euf
571190-30-2
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
EC-000.2350
Ibrance
|
Kinome_3823
Kinome_3824
LQQ
Palbociclib
PD 0332991
PD 332991, PD 0332991, PD0332991
PD0332991
PD-0332991
PD-332991
S1116_Selleck
|
|
23 |
|
Olaparib |
Approved |
Phase 2 |
|
763113-22-0 |
23725625 |
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
Acylpiperazine analogue, 47
AKOS005145764
AZD 2281
AZD2281
AZD-2281
|
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
olaparib
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
|
|
24 |
|
Memantine |
Approved, Investigational |
Phase 2 |
|
19982-08-2 |
4054 |
Synonyms:
1,3-Dimethyl-5-adamantanamine
1,3-Dimethyl-5-aminoadamantane
19982-08-2
1-Amino-3,5-dimethyladamantane
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-dimethyladamantan-1-amine
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
Axura
BBL000737
Biomol-NT_000209
BPBio1_001117
BPBio1_001270
BSPBio_001015
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DivK1c_000068
DMAA
Ebixa
EU-0053634
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
KBio2_006223
|
KBio3_001926
KBioGR_001543
KBioSS_001087
Lopac0_000861
LS-157051
Lundbeck brand OF memantine hydrochloride
Memantin
Memantina
Memantina [INN-Spanish]
memantine
Memantine
Memantine (INN)
Memantine [INN:BAN]
Memantine [INN]
Memantine HCL
Memantine hydrochloride
Memantine Hydrochloride
Memantinum
Memantinum [INN-Latin]
Merz brand OF memantine hydrochloride
MolPort-002-041-858
Namenda
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
Spectrum_000607
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
ST057652
STK520682
UNII-W8O17SJF3T
ZERO/006024
|
|
25 |
|
Vemurafenib |
Approved |
Phase 2 |
|
918504-65-1 |
23252090 42611257 |
Synonyms:
PLX4032
PLX-4032
R05185426
RG7204
RO5185426
|
vemurafenib
Vemurafenib
Vémurafénib
Vemurafenibum
Zelboraf
|
|
26 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
6442177 70789204 |
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
001, RAD
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
Everolimus
|
évérolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD, SDZ
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ RAD
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
27 |
|
Vinblastine |
Approved |
Phase 2 |
|
865-21-4 |
13342 241903 |
Synonyms:
(2a,2'b,3b,4a,5b)-VINCALEUKOBLASTINE
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(2Α,2'β,3β,4α,5β)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC1L21JC
AC1L68D2
AC1MXZJ2
AC-20335
BIDD:PXR0201
Bio-0111
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
C07201
C46H58N4O9
CCRIS 9002
Cell pharm brand OF vinblastine sulfate
Cellblastin
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EG labo brand OF vinblastine sulfate
EINECS 212-734-0
Faulding brand OF vinblastine sulfate
Gastrozepin brand OF vinblastine sulfate
Gry brand OF vinblastine sulfate
Hexal brand OF vinblastine sulfate
HMS2090K05
HSDB 3263
KBio3_003033
Lemblastine
Lemery brand OF vinblastine sulfate
Lilly brand OF vinblastine sulfate
|
LS-1859
LS-187263
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NChemBio.2007.10-comp22
nchembio873-comp22
NCI60_004200
NCI-C04842
NDC 0002-1452-01
Neuro_000020
Nincaluicolflastine
NSC 47842
Rozevin
SPBio_000680
Spectrum2_000890
Spectrum3_001994
STOCK1N-38480
Sulfate, vinblastine
UNII-5V9KLZ54CY
Velban
Velbe
Vinblastin
Vinblastin hexal
Vinblastina
Vinblastina (TN)
Vinblastina [Dcit]
Vinblastina [DCIT]
Vinblastina lilly
vinblastine
Vinblastine
Vinblastine (INN)
Vinblastine [INN:BAN]
Vinblastine sulfate
Vinblastine Sulfate
Vinblastinsulfat-gry
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
VLB
VR-8
|
|
28 |
|
Irinotecan |
Approved, Investigational |
Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
97682-44-5
AC1L1U0Z
AC1Q6PGI
AC-7469
Bio-0054
Biotecan
Biotecan (TN)
BRD-K08547377-003-02-4
BSPBio_002346
C16641
C33H38N4O6
Campothecin-11
Campto
Camptosar
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin 11
Camptothecin-11
CHEBI:105985
CHEMBL481
CID60838
CP0
CPT 11
CPT11
CPT-11
D08086
|
DB00762
FT-0083650
HSDB 7607
Irinophore C
irinotecan
Irinotecan
Irinotecan (INN)
Irinotecan [INN:BAN]
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan Hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan Hydrochloride Trihydrate
IRINOTECAN HYDROCHLORIDE Trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
LS-44589
NCI60_005051
NK012 Compound
NSC728073
S1198_Selleck
sn 38
sn-38
sn38 CPD
TL8006026
UNII-7673326042
|
|
29 |
|
nivolumab |
Approved |
Phase 1, Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
MDX-1106
nivolumab
|
|
|
30 |
|
Iodine |
Approved, Investigational |
Phase 2 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
diiodine
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
molecular iodine
Molecular iodine
Tincture iodine
|
|
31 |
|
carbamide peroxide |
Approved |
Phase 2 |
|
124-43-6 |
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
32 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
Anti-VEGF Humanized Monoclonal Antibody
anti-VEGF monoclonal antibody
Anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
rhuMAb-VEGF
|
|
33 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
|
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
34 |
|
Methotrexate |
Approved |
Phase 2 |
|
1959-05-2, 59-05-2 |
126941 |
Synonyms:
4-Amino-10-methylfolate
4-amino-10-methylfolic acid
4-Amino-10-methylfolic acid
4-Amino-N(10)-methylpteroylglutamate
4-amino-N(10)-methylpteroylglutamic acid
4-Amino-N(10)-methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Dicesium salt methotrexate
Emtexate
Emtexic acid
Folex
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate
|
Méthotrexate
Methotrexate hydrate
Methotrexate sodium
Methotrexate Sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
MTX
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
N-Bismethylpteroylglutamic Acid
Otrexup
Rheumatrex
Sodium, methotrexate
Trexall
Xatmep
|
|
35 |
|
Levoleucovorin |
Approved, Investigational |
Phase 2 |
|
68538-85-2 |
149436 |
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-Formyltetrahydrofolate
(6S)-5-formyltetrahydrofolic acid
(6S)-5-Formyltetrahydrofolic acid
(6S)-Folinate
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
6 S Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
ácido levofolínico
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid SF
Folinic acid-SF
Fusilev
Kunyrin
Leucoverin
|
Leucovorin
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leukovorin
Leukovorum
Levo leucovorin
Levofolene
Levofolinate
Levofolinic acid
Levoleucovorin
Levo-leucovorin
L-Folinate
L-Folinic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
36 |
|
Topotecan |
Approved, Investigational |
Phase 2 |
|
119413-54-6, 123948-87-8 |
60700 |
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
123948-87-8
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-[(Dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
Hydrochloride, nogitecan
Hydrochloride, topotecan
LS-127395
MLS000759456
NCGC00178695-01
NChemBio.2007.10-comp24
|
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
Nogitecan hydrochloride
NSC609699
SK And F 104864 a
SK And F104864a
SK And F-104864-a
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SmithKline beecham brand OF topotecan hydrochloride
SMP2_000312
SMP2_000327
SMR000466344
TOPO
topotecan
Topotecan
Topotecan (BAN)
Topotecan [INN:BAN]
Topotecan Hcl
Topotecan hydrochloride
Topotecan Hydrochloride
Topotecan lactone
Topotecan Lactone
Topotecan monohydrochloride, (S)-isomer
Topotecan Monohydrochloride, (S)-Isomer
TOPOTECAN, HYCAMTIN
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
UNII-7M7YKX2N15
|
|
37 |
|
Ritonavir |
Approved, Investigational |
Phase 2 |
|
155213-67-5 |
392622 |
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
38 |
|
Lopinavir |
Approved |
Phase 2 |
|
192725-17-0 |
92727 |
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
378, ABT
A 157378
A 157378.0
A-157378.0
A-157378-0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
ABT-378a-157378-0a-157378.0
AC1L3OPJ
AIDS032937
Aluviran
|
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Kaletra
Koletra
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
LPV
LS-173766
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
|
|
39 |
|
Tyrosine |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
60-18-4 |
6057 |
Synonyms:
(-)-a-Amino-p-hydroxyhydrocinnamate
(-)-a-Amino-p-hydroxyhydrocinnamic acid
(-)-alpha-Amino-p-hydroxyhydrocinnamate
(-)-alpha-Amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamate
(−)-α-amino-p-hydroxyhydrocinnamic acid
(-)-Α-amino-p-hydroxyhydrocinnamic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoate
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-Amino-3-(4-hydroxyphenyl)propanoic acid
(S)-(-)-Tyrosine
(S)-2-Amino-3-(4-hydroxyphenyl)propionic acid
(S)-2-Amino-3-(p-hydroxyphenyl)propionate
(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid
(S)-3-(p-Hydroxyphenyl)alanine
(S)-a-Amino-4-hydroxybenzenepropanoate
(S)-a-Amino-4-hydroxy-benzenepropanoate
(S)-a-Amino-4-hydroxybenzenepropanoic acid
(S)-a-Amino-4-hydroxy-benzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoate
(S)-alpha-Amino-4-hydroxy-benzenepropanoate
(S)-alpha-amino-4-Hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxybenzenepropanoic acid
(S)-alpha-Amino-4-hydroxy-benzenepropanoic acid
(S)-Tyrosine
(S)-Α-amino-4-hydroxybenzenepropanoate
(S)-α-amino-4-hydroxybenzenepropanoic acid
(S)-Α-amino-4-hydroxybenzenepropanoic acid
140-43-2
1991-85-1
25619-78-7
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate
2-Amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid
2-Amino-3-(p-hydroxyphenyl)propionic acid
2csm
3-(4-Hydroxyphenyl)-L-alanine
3-(p-Hydroxyphenyl)alanine
46209-14-7
4-hydroxy-L-phenylalanine
4-Hydroxy-L-phenylalanine
4ts1
55520-40-6
60-18-4
93829_FLUKA
93829_SIGMA
AB1002647
AC-11295
AC1L1LPI
AC1Q4U7L
AC1Q4U7M
AI3-09055
alpha-Amino-beta-(4-hydroxyphenyl)propionic acid
AR-1J3457
BB_NC-1194
Benzenepropanoate
Benzenepropanoic acid
beta-(p-Hydroxyphenyl)alanine
bmse000051
C00082
CHEBI:17895
CHEMBL925
CID6057
D00022
DB00135
|
DB03839
DD69927C-C6A8-4BC6-8E9A-0AB423B176E7
DTY
EINECS 200-460-4
FEMA No. 3736
Free-Form L-Tyrosine
HSDB 2003
H-Tyr-OH
L Tyrosine
L-(-)-Tyrosine
L-2-Amino-3-p-hydroxyphenylpropanoic acid
L-p-Tyrosine
LS-2336
L-Tyrosin
L-tyrosine
L-Tyrosine (9CI)
L-Tyrosine (JAN)
L-Tyrosine hydrochloride
L-Tyrosine, homopolymer
L-Tyrosine, monomer
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide
Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours
MolPort-001-792-016
NCGC00159350-02
NCGC00159350-03
nchembio.105-comp1
nchembio.121-comp7
nchembio.186-comp84
nchembio.284-comp7
nchembio816-comp11
NSC 82624
Para tyrosine
Para-tyrosine
p-Tyrosine
Rxosine
T0550
T3754_SIAL
T4321_SIAL
T4321_SIGMA
T8566_SIGMA
tirosina
Tirosina
Tirosina [Spanish]
tyr
Tyr
TYR NH3+ COOH
tyrosine
Tyrosine
TYROSINE
Tyrosine (USP/INN)
Tyrosine (VAN)
Tyrosine [USAN:INN]
Tyrosine Power
Tyrosine, L- (8CI)
Tyrosine, L isomer
Tyrosine, L-isomer
Tyrosinum
Tyrosinum [Latin]
UNII-42HK56048U
W373605_ALDRICH
Y
|
|
40 |
|
Methionine |
Approved, Nutraceutical |
Phase 2 |
|
63-68-3 |
6137 |
Synonyms:
(2S)-2-Amino-4-(methylsulfanyl)butanoate
(2S)-2-amino-4-(methylsulfanyl)butanoic acid
(2S)-2-Amino-4-(methylsulfanyl)butanoic acid
(2S)-2-Amino-4-(methylsulphanyl)butanoate
(2S)-2-Amino-4-(methylsulphanyl)butanoic acid
(L)-Methionine
(S)-(+)-Methionine
(S)-2-Amino-4-(methylthio)butanoate
(S)-2-Amino-4-(methylthio)-butanoate
(S)-2-amino-4-(methylthio)butanoic acid
(S)-2-Amino-4-(methylthio)butanoic acid
(S)-2-Amino-4-(methylthio)-butanoic acid
(S)-2-Amino-4-(methylthio)butyrate
(S)-2-amino-4-(methylthio)butyric acid
(S)-2-Amino-4-(methylthio)butyric acid
(S)-methionine
(S)-Methionine
2-Amino-4-(methylthio)butyrate
2-Amino-4-(methylthio)butyric acid
2-Amino-4-methylthiobutanoate
2-Amino-4-methylthiobutanoic acid
a-Amino-g-methylmercaptobutyrate
a-Amino-g-methylmercaptobutyric acid
Acimethin
alpha-Amino-alpha-aminobutyric acid
alpha-Amino-gamma-methylmercaptobutyrate
alpha-Amino-gamma-methylmercaptobutyric acid
Cymethion
gamma-Methylthio-alpha-aminobutyrate
gamma-Methylthio-alpha-aminobutyric acid
g-Methylthio-a-aminobutyrate
g-Methylthio-a-aminobutyric acid
H-Met-H
H-Met-OH
L(-)-Amino-alpha-amino-alpha-aminobutyric acid
L(-)-Amino-gamma-methylthiobutyric acid
L-(−)-methionine
L-(-)-Methionine
L-2-Amino-4-(methylthio)butyric acid
|
L-2-Amino-4methylthiobutyrate
L-2-Amino-4methylthiobutyric acid
L-2-Amino-4-methylthiobutyric acid
L-a-Amino-g-methylmercaptobutyrate
L-a-Amino-g-methylmercaptobutyric acid
L-a-Amino-g-methylthiobutyrate
L-a-Amino-g-methylthiobutyric acid
L-alpha-Amino-gamma-methylmercaptobutyrate
L-alpha-Amino-gamma-methylmercaptobutyric acid
L-alpha-Amino-gamma-methylthiobutyrate
L-alpha-Amino-gamma-methylthiobutyric acid
L-gamma-Methylthio-alpha-aminobutyric acid
Liquimeth
L-Isomer methionine
L-Methionin
L-Methionine
L-Methionine Z
L-Methioninum
L-Α-amino-γ-methylmercaptobutyrate
L-α-amino-γ-methylmercaptobutyric acid
L-Α-amino-γ-methylmercaptobutyric acid
M
Mepron
Met
Methilanin
Methionine
METHIONINE
Methionine, L isomer
Methionine, L-isomer
Methioninum
Metionina
Neo-methidin
Pedameth
Poly-L-methionine
Polymethionine
S-Methionine
S-Methyl-L-homocysteine
Toxin war
|
|
41 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
ácido fólico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
|
Folipac
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
42 |
|
Ensartinib |
Investigational |
Phase 2 |
|
1370651-20-9 |
|
43 |
|
tipifarnib |
Investigational |
Phase 2 |
|
192185-72-1 |
159324 |
Synonyms:
(R)-( )-R115777
(R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone
192185-72-1
1x81
2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H )-quinolinone
6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one
6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one
6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
AC1L4LN0
AC1Q3OVC
AR-1H0635
AR-1H0636
CCRIS 9329
CHEMBL289228
CID159324
D03720
IND58359
|
JAN
LS-184411
LS-187005
LS-187640
NSC-702818
R 115777
R-11577
R115777
R-115777
S1453_Selleck
tipifarnib
Tipifarnib
Tipifarnib (USAN/INN)
Tipifarnib [USAN]
UNII-MAT637500A
Zarnestra
Zarnestra, IND 58359, R115777, Tipifarnib
|
|
44 |
|
Camptothecin |
Experimental |
Phase 2 |
|
7689-03-4 |
|
Synonyms:
(+)-camptothecin
(+)-camptothecine
(S)-(+)-camptothecin
20(S)-camptothecine
|
21,22-Secocamptothecin-21-oic acid lactone
Camptothecine
D-camptothecin
|
|
45 |
|
Cadexomer iodine |
Experimental |
Phase 2 |
|
94820-09-4 |
|
Synonyms:
|
46 |
|
Imetelstat |
Investigational |
Phase 2 |
|
868169-64-6 |
|
Synonyms:
|
47 |
|
acivicin |
|
Phase 2 |
|
|
|
48 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
49 |
|
Immunoglobulin G |
|
Phase 2 |
|
|
|
50 |
|
Deoxyglucose |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 149)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial |
Unknown status |
NCT00517959 |
Phase 3 |
|
2 |
Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents |
Completed |
NCT00749723 |
Phase 2, Phase 3 |
carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide |
3 |
An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma |
Recruiting |
NCT02265770 |
Phase 2, Phase 3 |
16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy |
4 |
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years |
Active, not recruiting |
NCT01096368 |
Phase 3 |
Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine |
5 |
Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma |
Unknown status |
NCT00287924 |
Phase 2 |
methotrexate |
6 |
Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma |
Unknown status |
NCT00278252 |
Phase 2 |
etoposide |
7 |
Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas |
Unknown status |
NCT01721577 |
Phase 1, Phase 2 |
AXL1717 |
8 |
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy |
Completed |
NCT00463203 |
Phase 2 |
Bevacizumab;Irinotecan |
9 |
A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma |
Completed |
NCT00027846 |
Phase 2 |
carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna |
10 |
A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma |
Completed |
NCT00003309 |
Phase 2 |
cisplatin;cyclophosphamide;etoposide;vincristine sulfate |
11 |
Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation |
Completed |
NCT00006258 |
Phase 2 |
cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate |
12 |
A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients |
Completed |
NCT01462695 |
Phase 2 |
Sunitinib Malate |
13 |
Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma |
Completed |
NCT00095940 |
Phase 1, Phase 2 |
lapatinib ditosylate |
14 |
SIOP Study of Combined Modality Treatment in Childhood Ependymoma |
Completed |
NCT00004224 |
Phase 2 |
cyclophosphamide;etoposide;vincristine sulfate |
15 |
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma |
Completed |
NCT00883688 |
Phase 2 |
Bevacizumab;Lapatinib |
16 |
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma |
Completed |
NCT00826241 |
Phase 2 |
Temozolomide;Lapatinib |
17 |
Phase II Study of Bevacizumab Plus Irinotecan (Camptosarâ„¢) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas |
Completed |
NCT00381797 |
Phase 2 |
Irinotecan Hydrochloride |
18 |
CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy |
Completed |
NCT00008008 |
Phase 2 |
cyclophosphamide;thiotepa |
19 |
A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS |
Completed |
NCT00002876 |
Phase 2 |
cisplatin;etoposide |
20 |
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas |
Completed |
NCT01125046 |
Phase 2 |
|
21 |
A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors |
Completed |
NCT00091182 |
Phase 2 |
oxaliplatin |
22 |
Phase II Trial of Irinotecan in Children With Refractory Solid Tumors |
Completed |
NCT00004078 |
Phase 2 |
irinotecan hydrochloride |
23 |
Proton Radiation for Low Grade Gliomas |
Completed |
NCT01024907 |
Phase 1, Phase 2 |
|
24 |
A Phase II Study of Pemetrexed in Children With Recurrent Malignancies |
Completed |
NCT00520936 |
Phase 2 |
pemetrexed |
25 |
A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage |
Completed |
NCT00492089 |
Phase 2 |
bevacizumab;placebo |
26 |
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) |
Recruiting |
NCT04374305 |
Phase 2 |
Brigatinib |
27 |
Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG |
Recruiting |
NCT04049669 |
Phase 2 |
Indoximod;Indoximod;Temozolomide;Cyclophosphamide;Etoposide;Lomustine |
28 |
A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors |
Recruiting |
NCT03220646 |
Phase 2 |
abemaciclib;abemaciclib |
29 |
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial |
Recruiting |
NCT01295944 |
Phase 2 |
Carboplatin;Bevacizumab |
30 |
Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma |
Recruiting |
NCT03727841 |
Phase 2 |
Marizomib |
31 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations |
Recruiting |
NCT04195555 |
Phase 2 |
Ivosidenib |
32 |
A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma and ATRT |
Recruiting |
NCT01356290 |
Phase 2 |
Bevacizumab;Thalidomide;Celecoxib;Fenofibric acid;Etoposide;Cyclophosphamide;Etoposide phosphate;Cytarabine |
33 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations |
Recruiting |
NCT04320888 |
Phase 2 |
Selpercatinib |
34 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes |
Recruiting |
NCT03526250 |
Phase 2 |
Palbociclib |
35 |
Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors |
Recruiting |
NCT03095248 |
Phase 2 |
Selumetinib |
36 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations |
Recruiting |
NCT03210714 |
Phase 2 |
Erdafitinib |
37 |
Methionine PET/CT Studies In Patients With Cancer |
Recruiting |
NCT00840047 |
Phase 2 |
Methionine |
38 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes |
Recruiting |
NCT03233204 |
Phase 2 |
Olaparib |
39 |
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors |
Recruiting |
NCT03213678 |
Phase 2 |
Samotolisib |
40 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations |
Recruiting |
NCT03213652 |
Phase 2 |
Ensartinib |
41 |
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study |
Recruiting |
NCT03194906 |
Phase 2 |
Memantine |
42 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions |
Recruiting |
NCT03213704 |
Phase 2 |
Larotrectinib;Larotrectinib Sulfate |
43 |
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers |
Recruiting |
NCT03173950 |
Phase 2 |
Nivolumab |
44 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol |
Recruiting |
NCT03155620 |
Phase 2 |
Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib |
45 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations |
Recruiting |
NCT03698994 |
Phase 2 |
Ulixertinib |
46 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations |
Recruiting |
NCT04284774 |
Phase 2 |
Tipifarnib |
47 |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations |
Recruiting |
NCT03220035 |
Phase 2 |
Vemurafenib |
48 |
A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects |
Active, not recruiting |
NCT00187226 |
Phase 2 |
|
49 |
A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma |
Active, not recruiting |
NCT02125786 |
Phase 2 |
^1^8F-Fluorodeoxyglucose;^1^1C-methionine |
50 |
Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma |
Active, not recruiting |
NCT02155920 |
Phase 2 |
Everolimus |
Inferred drug relations via
UMLS
71
/
NDF-RT
51
:
|